{"url_path":"/sec/eltp/8-k/2026-06-01/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 ****Regulation FD","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1053369/0001493152-26-026519-index.html","accession_number":"0001493152-26-026519","cik":"0001053369","ticker":"ELTP","issuer_name":"ELITE PHARMACEUTICALS INC /NV/","edgar_url":"https://www.sec.gov/Archives/edgar/data/1053369/0001493152-26-026519-index.html","primary_entity_key":"0001053369","primary_entity_name":"ELITE PHARMACEUTICALS INC /NV/"},"word_count":158,"has_tables":true,"body_markdown":"**Item\n7.01****Regulation FD\nDisclosure.**\n\n \n\nOn\nJune 1, 2026, in a press release, Elite Pharmaceuticals, Inc., or Elite, reported that it had filed an Abbreviated New Drug Application\nwith the US Food and Drug Administration for a generic version of an undisclosed drug product in the class of medications called anticoagulants.\n\n \n\nA\ncopy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information set forth in this Item 7.01\nand contained in the press release furnished as Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the\nSecurities Exchange Act of 1934, as amended, or the Exchange Act, and is not incorporated by reference into any of Elite’s filings\nunder the Securities Act of 1933, as amended, or the Securities Act, or the Exchange Act, whether made before or after the date hereof,\nexcept as shall be expressly set forth by specific reference in any such filing."}